UNSPSC 51422311: Mazipredone

This classification denotes a therapeutic glucocorticoid with the molecular formula C26H38N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QN0W2YSW63, chemically known as 11beta,17-dihydroxy-21-(4-methyl-1-piperazinyl)pregna-1,4-diene-3,20-dione. but generally known as mazipredone, which bears US NIH Compound Identifier 6064. European Medicines Agency schedules Mazipredone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08657MIG.

UNSPSC 51422311 Mazipredone (Commodity) covers pharmaceutical products, though recent state and local solicitations under this code show activity in naloxone and drug deactivation systems procurement rather than the specific drug named in the code. Seminole County, Florida issued an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, while the Texas Health and Human Services Commission posted a Request for Information in April 2026 to explore direct-to-manufacturer prescription fulfillment models. The issuing bodies reflect health and human services procurement — county public health functions and state HHS agencies — seeking to support community health and pharmacy benefit management objectives. Vendors must meet standard compliance requirements including drug-free workplace certification, E-Verify eligibility verification, and appropriate insurance coverages; the Seminole County contract carries a three-month probationary termination clause and potential FEMA funding implications.

Geographic activity centers on Florida and Texas in the recent record. The Seminole County IFB (solicitation IFB60459723LAS, response deadline July 26, 2023) is the only closed procurement activity present; it requires electronic submission through the county's e-Procurement Portal and includes an initial two-year term with one-year renewal option. The Texas HHS RFI (HHS0017013, posted April 3, 2026) functions as exploratory market research to inform future formal procurement rather than an immediate buying opportunity, gathering vendor capability data on direct-to-manufacturer contracting models and pricing flexibility. No explicit set-aside designations appear in either opportunity, and no award values are stated.